Natural history and treatment effects in Guillain-Barré syndrome: A multicentre study

Archives of Disease in Childhood

Volumn 74, Issue 4, 1996, Pages 281-287

  Korinthenberg, R ^a   Schulte Monting J ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b NONE

Author keywords

Guillain Barr syndrome; Treatment

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN;

ADOLESCENT; ARTICLE; CHILD; DEMYELINATING NEUROPATHY; DISEASE COURSE; FOLLOW UP; GUILLAIN BARRE SYNDROME; HUMAN; INFANT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PLASMAPHERESIS; POLYNEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE; SYMPTOMATOLOGY; WALKING;

ACUTE DISEASE; ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; MALE; PLASMAPHERESIS; POLYRADICULONEUROPATHY; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; WALKING;

EID: 0029990123     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.74.4.281     Document Type: Article

References (53)

1. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome.Ann Neurol 1990; 27 (suppl): S21-4.
2. Guillain-Barré Syndrome Study Group. Plasmapheresis for acute Guillain-Barré syndrome. Neurology 1985; 35: 1096-104.
3. French Cooperative Group in plasma exchange in Guillain-Barré syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 1987; 22: 753-61.
4. Shahar E, Murphy EG, Roifman CM. Benefit of intravenously administered immune serum globulin in patients with Guillain-Barré syndrome. J Pediatr 1990; 116: 141-4.
5. van der Meché FGA, Schmitz PIM, and the Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992; 326: 1123-9.
6. Ceccarelli M, Assanta N, Chiaravalloti G, Rocopou C, Caiulo VA. Intravenous immunoglobulin treatment in Guillain-Barré syndrome. Minerva Pediatr 1992; 44: 237-40.
7. Vallée L, Dulac O, Nuyts JP, Leclerc F, Vamecq J. Intravenous immune globulin is also an efficient therapy of acute Guillain-Barré syndrome in affected children. Neuropediatrics 1993; 24: 235-6.
8. Notarangelo LD, Duse M, Tiberti S, et al. Intravenous immunoglobulin in two children with Guillain-Barré syndrome. Eur J Pediatr 1993; 152: 372-4.
9. Sakakihara Y, Kamoshita S. Age-associated changes in the symptomatology of Guillain-Barré syndrome in children. Dev Med Child Neurol 1991; 33: 611-6.
10. Rantala H, Cherry JD, Shields WD, Uhari M. Epidemiology of Guillain-Barré syndrome in children: relationship of oral polio vaccine administration to occurrence. J Pediatr 1994; 124: 220-3.
11. Hart DE, Rojas LA, Rosario JA, Recalde H, Roman GC. Childhood Guillain-Barré syndrome in Paraguay, 1990 to 1991. Ann Neurol 1994; 36: 859-63.
12. Hughes RAC. Guillain-Barré syndrome. Berlin: Springer, 1990.
13. Hartung HP, Pollard JD, Harvey JK, Toyka KV. Immunopathogenesis and treatment of the Guillain-Barré syndrome part II. Muscle Nerve 1995; 18: 154-64.
14. Winer JB, Hughes RA, Osmond C. A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value. J Neurol Neurosurg Psychiatry 1988; 51: 605-12.
15. Siemes H, Emerich R, Merlin M, Reitter B. Die akute Polyradikuloneuritis (Guillain-Barré Syndrom) im Kindesalter. Klin Pädiatr 1983; 195: 38-44.
16. Briscoe DM, McMenamin JB, O'Donohoe NV. Prognosis in Guillain-Barré syndrome. Arch Dis Child 1987; 62: 733-5.
17. Bos AP, van der Meche FGA, Witsenburg M, van der Voort E. Experiences with Guillain-Barré syndrome in a pediatric intensive care unit. Intensive Care Med 1987; 13: 328-31.
18. Rantala H, Uhari M, Niemelä M. Occurrence, clinical manifestations, and prognosis of Guillain-Barré syndrome. Arch Dis Child 1991; 66: 706-9.
19. Bradshaw DY, Jones HR. Guillain-Barre syndrome in children: clinical course, electrodiagnosis, and prognosis. Muscle Nerve 1992; 15: 500-6.
20. Hung KL, Wang HS, Liou WY, et al. Guillain-Barré syndrome in children: a cooperative study in Taiwan. Brain Dev 1994; 16: 204-8.
21. Kleyweg RP, van der Meche FG, Loonen MC, de Jonge J, Knip B. The natural history of the Guillain-Barré syndrome in 18 children and 50 adults. J Neurol Neurosurg Psychiatry 1989; 52: 853-6.
22. Rossi LN, Mumenthaler M, Lütschg J, Ludin HP, Guillain-Barré syndrome in children with special reference to the natural history of 38 personal cases. Neuropadiatrie 1976; 7: 42-51.
23. Oh SJ. Subacute demyelinating polyneuropathy responding to corticosteroid treatment. Arch Neurol 1978; 35: 509-16.
24. Colan RV, Carter Snead III O, Oh SJ, Benton JW. Steroidresponsive polyneuropathy with subacute onset in childhood. J Pediatr 1980; 97: 374-7.
25. Korinthenberg R, Sauer M. Das Guillain-Barré Syndrom im Kindesalter. Monatsschr Kinderheilkd 1992; 140: 792-8.
26. Guillain-Barré Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 1993; 341: 586-90.
27. The Dutch Guillain-Barré Study Group. Treatment of Guillain-Barre syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study. Ann Neurol 1994; 35: 749-52.
28. Epstein MA, Sladky JT. The role of plasmapheresis in childhood Guillain-Barré syndrome. Ann Neurol 1990; 28: 65-9.
29. Vajsar J, Sloane A, Wood E, Murphy EG. Plasmapheresis vs intravenous immunoglobulin treatment in childhood Guillain-Barré syndrome. Arch Pediatr Adolesc Med 1994; 148: 1210-2.
30. Hammerejö JA. Plasma exchange in childhood Guillain-Barré syndrome. Acta Paediatr 1995; 84: 355.
31. Kleyweg RP, van der Meche FG, Meulstee J. Treatment of Guillain-Barré syndrome with high-dose gammaglobulin. Neurology 1988; 38: 1639-41.
32. Schuchardt V, Hotz M, Hund E, Sun S, Heitmann R, Hacke W. Erfahrungen mit hochdosiertem Immunoglobulin G bei neuromuskularen Erkrankungen. Nervenarzt 1993; 64: 98-103.
33. Jackson MC, Godwin-Austen RB, Whiteley AM. High-dose intravenous immunoglobulin in the treatment of Guillain-Barré syndrome: a preliminary open study. J Neurol 1993; 240: 51-3.
34. Ng KKP, Howard RS, Hirsch NP, Miller DH. Intravenous immunoglobulin versus plasma exchange in Guillain-Barré syndrome. Neurology 1993; 43: 2729.
35. Irani DN, Cornblath DR, Chaudhry V, Borel C, Hanley DF. Relapse in Guillain-Barré syndrome after treatment with human immune globulin. Neurology 1993; 43: 872-5.
36. Castro LHM, Ropper AH. Human immune globulin infusion in Guillain-Barré syndrome: worsening during and after treatment. Neurology 1993; 43: 1034-6.
37. Kleyweg RP, van der Meche FG. Treatment related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma-exchange. J Neurol Neurosurg Psychiatry 1991; 54: 957-60.
38. van der Meche FGA. The Guillain-Barré syndrome: plasma exchange or immunoglobulins intravenously. J Neurol Neurosurg Psychiatry 1994; 57 (suppl): 33-4.
39. Raphael JC, Chastang C, Gajdos PH. Intravenous immune globulin versus plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992; 327: 816.
40. Ropper AH. The Guillain-Barré syndrome. N Engl J Med 1992; 326: 1130-6.
41. Cornblath DR, Hughes RAC. Guillain-Barré syndrome: the evolution of therapy. J Neurol 1994; 241: 404-5.
42. Arakawa Y, Yoshimura M, Kobayashi K, Miyao M, Momoi Y, Yanagisawa M. The use of intravenous immunoglobulin in Miller Fisher syndrome. Brain Dev 1993; 15: 231-3.
43. Horneff G, Huppertz HI, Muller K, Voit T, Karch H. Demonstration of Borrelia burgdorferi infection in a child with Guillain-Barré syndrome. Eur J Pediatr 1993; 152: 810-2.
44. Al-Qudah A. Immunoglobulins in the treatment of Guillain-Barré syndrome in early childhood. J Child Neurol 1994; 9: 178-80.
45. McGhee B, Jarjour IT. Single-dose intravenous immune globulin for treatment of Guillain-Barré syndrome. Am J Hosp Pharm 1994; 51: 97-9.
46. Constantopoulos A, Langona E. Intravenous immune globulin in children with Guillain-Barré syndrome. Neuropediatrics 1994; 25: 165.
47. Cusmai R, Bertini E, Bianchi F. Intravenous immunoglobulin in childhood Guillain-Barré syndrome [abstr]. Ann Neurol 1993; 34: 446.
48. Shahar EM, Roifman CM, Shorer Z. High dose intravenous gamma globulins are effective in severe pediatric Guillain-Barré syndrome: a prospective follow-up study of 23 cases [abstr]. Ann Neurol 1994; 36: 503.
49. Gürses N, Uysal S, Cetinkaya F, Islek I, Kalayci AG. Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. Scand J Infect Dis 1995; 27: 241-3.
50. Watson JDG, Gibson J, Joshua DE, Kronenberg H. Aseptic meningitis associated with high dose intravenous immunoglobulin therapy. J Neurol Neurosurg Psychiatry 1991; 54: 275-6.
51. Comenzo RL, Malachowski ME, Meissner HC, Fulton DR, Berkman EM. Immune hemolysis, disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease. J Pediatr 1992; 120: 926-8.
52. Tan E, Hajinazarian M, Bay W, Neff J, Mendell JR. Acute renal failure resulting from intravenous immunoglobulin therapy. Arch Neurol 1993; 50: 137-9.
53. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994; 44: 223-6.